| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| ln Vitro |
One type of sulfonamide antibiotic is sulfadimethoxine. Numerous infections, including those of the intestine, bladder, respiratory system, and soft tissues, can be treated with sulfadimethoxine.
|
|---|---|
| References |
[1]. AGUIRRE M, [Sulfadimethoxine in various infections. Results]. Rev Clin Esp. 1961 Sep 30;82:394-9.
[2]. Guerard JJ, et al. Photochemical fate of sulfadimethoxine in aquaculture waters. Environ Sci Technol. 2009 Nov 15;43(22):8587-92. |
| Additional Infomation |
Sulfadimethoxine is a sulfonamide compound composed of a pyrimidine ring with methoxy substituents at positions 2 and 6, and a 4-aminobenzenesulfonamide group at position 4. It possesses multiple functions, including anti-infective, antibacterial, xenobiotic, environmental pollutant, and drug allergen activity. It belongs to the pyrimidine, sulfonamide, substituted aniline, aromatic ether, and sulfonamide antibiotic classes. Its functions are related to sulfonamide compounds. Sulfadimethoxine is a sulfonamide antibiotic used to treat various infections, including respiratory, urinary tract, intestinal, and soft tissue infections. Although approved for human use in some countries, it is most commonly used in veterinary medicine. Sulfadimethoxine inhibits bacteria from synthesizing folic acid (pteroylglutamate) from p-aminobenzoic acid. Sulfadimethoxine is approved for human use in Russia, including in children, and has been successfully used there for over 35 years. It is widely sold in Russia as an over-the-counter drug manufactured by several Russian pharmaceutical companies. In the United States, Sulfadimethoxine is one of the products withdrawn from the market or removed from shelves due to being found unsafe or ineffective.
It has been reported that sulfadimidine is present in Brassica napus, and relevant data are available. Sulfadimethoxine is a long-acting sulfonamide antibiotic used in veterinary medicine. Sulfadimethoxine inhibits bacterial folic acid synthesis by competing with para-aminobenzoic acid (PABA) for binding sites on dihydropteroate synthase. A sulfonamide anti-infective drug. See also: sulfadimidine sodium (in salt form); ometoprine; sulfadimidine (ingredient). IndicationsFor the treatment of infections. PharmacodynamicsSulfadimethoxine has been shown to be effective against Streptococcus, Klebsiella, Proteus, Shigella, Staphylococcus, Escherichia coli, and Salmonella. |
| Molecular Formula |
C12H14N4O4S
|
|---|---|
| Molecular Weight |
310.328
|
| Exact Mass |
310.073
|
| CAS # |
122-11-2
|
| Related CAS # |
Sulfadimethoxine sodium;1037-50-9;Sulfadimethoxine-d4;1020719-80-5;Sulfadimethoxine-d6;73068-02-7;Sulfadimethoxine-13C6;1334378-48-1
|
| PubChem CID |
5323
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
548.5±60.0 °C at 760 mmHg
|
| Melting Point |
200 °C
|
| Flash Point |
285.5±32.9 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.623
|
| LogP |
1.48
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
21
|
| Complexity |
420
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C1C([H])=C([H])C(=C([H])C=1[H])N([H])[H])(N([H])C1=C([H])C(=NC(=N1)OC([H])([H])[H])OC([H])([H])[H])(=O)=O
|
| InChi Key |
ZZORFUFYDOWNEF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H14N4O4S/c1-19-11-7-10(14-12(15-11)20-2)16-21(17,18)9-5-3-8(13)4-6-9/h3-7H,13H2,1-2H3,(H,14,15,16)
|
| Chemical Name |
4-amino-N-(2,6-dimethoxypyrimidin-4-yl)benzenesulfonamide
|
| Synonyms |
NSC 683544; NSC 683544; NSC 683544
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~322.24 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.06 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.06 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.06 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2224 mL | 16.1119 mL | 32.2238 mL | |
| 5 mM | 0.6445 mL | 3.2224 mL | 6.4448 mL | |
| 10 mM | 0.3222 mL | 1.6112 mL | 3.2224 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
